Pluripotent and myeloid-committed CD34+ subsets in hematopoietic stem cell allografts

Theilgaard‐Mönch, Kim; Raaschou‐Jensen, Klas; Schjodt, Katharine; Heilmann, Carsten; Vindeløv, Lars L.; Jacobsen, N; Dickmeiss, Ebbe

doi:10.1038/sj.bmt.1704297

Cited by 16 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…, primitive, and pluripotent SCs that can self-renew and generate committed progenitors of both the myeloid and lymphoid compartments. Although CD34 is not a universal marker for UCB-derived SCs [21], it has been used as a convenient marker for human hematopoietic stem or progenitor cells for autologous and allogeneic transplantation, resulting in the reconstitution of all hematopoietic lineages [22]. Most colony-forming cells are found within the CD34 ?…”

Section: Hematopoietic Stem Cellsmentioning

confidence: 99%

Stem and progenitor cells in human umbilical cord blood

et al. 2010

View full text Add to dashboard Cite

Both stem cells and progenitor cells are present in umbilical cord blood (UCB) at a high frequency, making these cells a major target population for experimental and clinical studies. As the use of autologous or allogeneic hematopoietic stem cell transplantation in the treatment of various diseases has grown rapidly in recent years, the concept of UCB banking for future use has drawn increasing interest. Stem and progenitor cells derived from UCB offer multiple advantages over adult stem cells, such as their immaturity (which may play a significant role in reducing rejection after transplantation into a mismatched host) and ability to produce large quantities of homogeneous tissue or cells. These cells can also differentiate across tissue lineage boundaries into neural, cardiac, epithelial, hepatic, and dermal tissues. Human UCB provides an alternative cell source that is ethically acceptable and widely supported by the public. This paper summarizes the characteristics of human UCB-derived stem and progenitor cells and their potential therapeutic use for tissue and cell regeneration.

show abstract

Section: Hematopoietic Stem Cellsmentioning

confidence: 99%

Stem and progenitor cells in human umbilical cord blood

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Interestingly, these cells are contained in human CD34 1 cells in bone morrow and umbilical cord blood (CB), although the CD34 1 is not a universal marker of all human HSCs [4]. Until recently, CD34 1 has been used as a convenient marker for human HSCs for autologous and allogeneic transplantations, resulting in a rapid reconstitution of all hematopoietic lineages [5]. CD34 1 cells derived from both BM cells and umbilical CB may not have major functional differences in hematopoiesis, although platelet recovery was slower after transplantation with CB cells than with cells from BM and peripheral blood sources [6,7].…”

Section: Introductionmentioning

confidence: 99%

Insights into human CD34+ hematopoietic stem/progenitor cells through a systematically proteomic survey coupled with transcriptome

Liu

Fan

et al. 2006

Proteomics

View full text Add to dashboard Cite

Hematopoietic stem cells are capable of self-renewal and differentiation into different hematopoietic lineages. To gain a comprehensive understanding of hematopoietic stem/progenitor cells, a systematic proteomic survey of human CD34+ cells collected from human umbilical cord blood was performed, in which the proteins were separated by 1- and 2-DE, as well as by nano-LC, and subsequently identified by MS. A total of 370 distinct proteins identified from those cells provided new insights into the potential of the stem/progenitor cells because the nerve, gonad, and eye-associated proteins were reliably identified. Interestingly, the transcripts of 133 (35.9%) identified proteins were not found by the prevalent transcriptome approaches, although several selected transcripts could be detected by RT-PCR. Moreover, the heterogeneity of 33 proteins identified from 2-DE was attributable primarily to post-translational processes rather than to alternative splicing at transcriptional level. Furthermore, the biosyntheses of 15 proteins identified in this study appears not to be completely interrupted in spite of the fact that corresponding antisense RNAs were found in the existing transcriptome data. The integrated proteomic and transcriptomic analyses employed here provided a unique view of the human stem/progenitor cells.

show abstract

“…The CD90 marker is known to be expressed by hematopoietic progenitors with the highest proliferative potential in vitro [ 28 – 30 ]. It was also reported that CD34 + CD90 + population contained mainly CD34 + CD90 + CD38 low cells being early-committed HPCs [ 31 ]. Hence, the different level of CD90 expression may evidence the higher content of early-committed HPCs in the FTPT compared to the CB.…”

Section: Discussionmentioning

confidence: 99%

“…We investigated the CD33 expression on the HPCs. The CD33 belongs to markers of the early myeloid differentiation stage [ 36 ] and the CD34 + CD33 + cells are myeloid progenitors [ 24 ], namely, early ones [ 31 ]. Similarly to the CB, the FTPT contained early myeloid progenitors.…”

Section: Discussionmentioning

confidence: 99%

Comparative Analysis of the Hematopoietic Progenitor Cells from Placenta, Cord Blood, and Fetal Liver, Based on Their Immunophenotype

Кучма

Кyryk

Svitina

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

We have investigated the characteristics of human hematopoietic progenitor cells (HPCs) with the CD34+CD45lowSSClow phenotype from full-term placental tissue (FTPT) as compared to cord blood (CB) and fetal liver (FL) cells. We demonstrated the presence of cell subpopulations at various stages of the differentiation with such immunophenotypes as CD34+/lowCD45low/−, CD34++CD45low/−, CD34+++CD45low/−, CD34+/lowCD45hi, and CD34++CD45hi in both first trimester placental tissue (FiTPT) and FTPT which implies their higher phenotypic heterogeneity compared to CB. HPCs of the FTPT origin expressed the CD90 antigen at a higher level compared to its expression by the CB HPCs and the CD133 antigen expression being at the same level in both cases. The HPCs compartment of FTPT versus CB contained higher number of myeloid and erythroid committed cells but lower number of myeloid and lymphoid ones compared to FL HPCs. HPCs of the FTPT and CB origin possess similar potentials for the multilineage differentiation in vitro and similar ratios of myeloid and erythroid progenitors among the committed cells. This observation suggests that the active hematopoiesis occurs in the FTPT. We obtained viable HPCs from cryopreserved placental tissue fragments allowing us to develop procedures for banking and testing of placenta-derived HPCs for clinical use.

show abstract

Pluripotent and myeloid-committed CD34+ subsets in hematopoietic stem cell allografts

Cited by 16 publications

References 24 publications

Stem and progenitor cells in human umbilical cord blood

Stem and progenitor cells in human umbilical cord blood

Insights into human CD34+ hematopoietic stem/progenitor cells through a systematically proteomic survey coupled with transcriptome

Comparative Analysis of the Hematopoietic Progenitor Cells from Placenta, Cord Blood, and Fetal Liver, Based on Their Immunophenotype

Contact Info

Product

Resources

About